We are live on
!
Find out more
MC
Muhlenkamp & Co Portfolio holdings
AUM
$380M
1-Year Est. Return
43.74%
This Fund
S&P 500
This Quarter
Est. Return
-2.07%
1 Year Est. Return
+43.74%
3 Year Est. Return
+121.38%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$260M
AUM Growth
-$12.2M
(-4.5%)
Cap. Flow
-$4.07M
Cap. Flow
% of AUM
-1.56%
Top 10 Holdings %
Top 10 Hldgs %
49.51%
Holding
34
New
1
Increased
–
Reduced
27
Closed
2
Top Buys
| 1 |
EQC
Equity Commonwealth
EQC
|
+$2.97M |
Top Sells
| 1 |
Biogen
BIIB
|
+$6.31M |
| 2 |
NVTA
Invitae Corporation
NVTA
|
+$216K |
| 3 |
Cameco
CCJ
|
+$72.1K |
| 4 |
MasTec
MTZ
|
+$51.3K |
| 5 |
Microchip Technology
MCHP
|
+$27K |
Sector Composition
| 1 | Technology | 19.3% |
| 2 | Industrials | 17.47% |
| 3 | Healthcare | 15.47% |
| 4 | Consumer Discretionary | 14.84% |
| 5 | Financials | 11.98% |
Similar funds
AC
MW
EAM
RWA
CSWG
BP
NICM
KFS
Muhlenkamp & Co's Q3 2021 Portfolio in Review
As of Q3 2021, Muhlenkamp & Co held 34 positions worth $260M, down 4.5% from $273M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Muhlenkamp & Co's Q3 2021 filing shows 1 new, 27 reduced and 2 closed positions. Its largest new stake was Equity Commonwealth: 112,943 shares worth $2.93M. The largest sale was Biogen, an estimated $6.31M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Industrials and Healthcare.
- Muhlenkamp & Co's largest Q3 2021 buy was Equity Commonwealth: 112,943 shares worth $2.93M.
- Muhlenkamp & Co's biggest Q3 2021 reduction was Cameco, cutting an estimated $72.1K.
- Muhlenkamp & Co fully exited Biogen in Q3 2021, selling an estimated $6.31M.
- Muhlenkamp & Co's ten largest holdings make up 50% of its $260M portfolio in Q3 2021.
- Muhlenkamp & Co opened 1 new position and closed 2 in Q3 2021.
- Muhlenkamp & Co's portfolio value fell 4.5% quarter-over-quarter to $260M.
Based on Muhlenkamp & Co's 13F filing for Q3 2021, filed 10 Dec 2021.